Caredx announces largest landmark study of its kind on antibody mediated rejection in heart transplantation published in journal of the american college of cardiology: heart failure

South san francisco, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the second study from surveillance heartcare outcomes registry (shore) in the journal of the american college of cardiology: heart failure. it is the largest prospective analysis of antib.
CDNA Ratings Summary
CDNA Quant Ranking